ClinicalTrials.gg
RecruitingNCT07485296POST-BIOUpdated Mar 20, 2026

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

A Phase 2 interventional study of Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic. and placebo capsule in Head & Neck Squamous Cell Carcinoma, sponsored by Gruppo Oncologico del Nord-Ovest. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Gruppo Oncologico del Nord-Ovest · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy — 44 open to participants now, 62 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Italy.

Planned enrollment
94th of 109
45 · median 194
Started
2026
with 4 others
Phase 2
35 of 129
6 open now
Primary completion
2030-12
later than 60 of 61 live
Registered
121st of 129
by date
Lead sponsor
5 of 129
Gruppo Oncologico del Nord-Ovest

Among the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, this one is the 94th largest by planned enrollment of the 109 interventional ones that give a count, is one of 5 that started in 2026, is one of 35 in phase 2, reaches primary completion later than 60 of the 61 other live ones, and was the 121st registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

44 of the 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Squamous Cell Carcinoma of Head and Neck with a site in Italy, or all of them as a file.
02

Study summary

phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC) treated with in first line pembrolizumab as standard of care (SoC).

The selected patient population will be randomised to receive the postbiotics Postbiotix-HLA™ or placebo for 4 cycles while in treatment with pembrolizumab as per clinical practice.

03

Conditions studied

  • Head & Neck Squamous Cell Carcinoma

Keywords

  • recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

-Inclusion Criteria

  1. Be willing and able to provide for the trial and its procedure;
  2. Histological confirmation of HNSCC;
  3. Advanced (not amenable to curative surgery or radiation therapy) or (AJCC Stage IV) HNSCC;
  4. For oropharyngeal cancers, known IHC p16+ and/or ISH HPV status;
  5. Positive Combined Proportionate Score (CPS);
  6. Presence of neoplastic lesion deemed safely accessible for tumor by the investigator;
  7. No prior systemic therapy for RM HNSCC;
  8. Eligible to receive pembrolizumab as the standard of care
  9. Performance Status ≤ 2;
  10. as per 1.1;
  11. Males and females, ages ≥18;
  12. Adequate renal function defined as calculated ≥30 milliliters per minute (mL/min) per the Cockcroft and Gault formula or Serum creatinine \< 1.5 x (ULN);
  13. Adequate liver function defined by or ALT \< 3 x ULN (\< 5 x ULN if liver metastases are present), and total \< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin up to 3.0 mg/dL);
  14. Adequate bone marrow function defined by any of the following laboratory test findings: - WBC > 2,000/mm3, Neutrophils > 1,500/mm3, > 100,000/mm3;
  15. Female subjects of should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;
  16. Female subjects of childbearing potential must be willing to use an adequate method of as outlined in Section 6.3 and 6.4 - Contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
  17. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 6.3 and 6.4 - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; 18.

Willingness to provide blood, buccal swab samples, stool samples and tissue (if deemed safe by the investigator) for translational research.

- Exclusion Criteria

  1. Presence of untreated . Patients with treated brain metastases must be stable for 4 weeks after completion of treatment and have documented stability on pre-study imaging. Patients must have no clinical symptoms from brain metastases and have no requirement for systemic amounting to >10 mg/day of prednisone or its equivalent for at least 2 weeks prior to first dose of study drug. Patients with known are excluded, even if treated.
  2. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  3. Any active or recent history of a known or suspected disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll.
  4. Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring treatment with systemic steroids
  5. Current use, or intent to use, probiotics, yogurt or bacterial fortified foods during the period of treatment.
  6. Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  7. Uncontrolled adrenal insufficiency.
  8. Known medical condition (e.g., a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
  9. Not recovered to ≤ Grade 1 toxicities related to any prior therapy before administration of study drug.
  10. Women who are pregnant or breastfeeding.
  11. History of myocarditis or congestive heart failure (as defined by Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry
  12. Any of the following laboratory test findings:

    • WBC \< 2,000/mm3
    • Neutrophils \< 1,500/mm3
    • Platelets \< 100,000/mm3
    • AST or ALT > 3 x ULN (> 5 x ULN if liver metastases are present)
    • Total bilirubin > 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin 3.0 mg/dL)
    • Calculated creatinine clearance \<30 millimeters per minute (mL/min) per the Cockcroft and Gault formula or serum creatinine >1.5 x upper limit of normal (ULN)
  13. Has a known history of (HIV) (HIV 1/2 antibodies).
  14. Has known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected).
  15. Has a known history of active TB (Bacillus Tuberculosis)
  16. Has previously received an organ transplant
  17. Has previously received bone marrow transplantation
  18. Has received a within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Arm

    * Placebo 1 capsule (400 mg) daily PO from cycle 1 day 1 up to cycle 5 day1 (i.e. 4 cycles); * Pembrolizumab 200 mg q21 up to tumor progression, intolerable toxicities or 35 cycles (approximately 2 years of therapy).

    Dietary Supplement: placebo capsule · Drug: Pembolizumab

  • Active comparator
    Postbiotic Arm

    * Postbiotix-HLA™, 1 capsule (400 mg) daily PO from cycle 1 day 1 up to cycle 5 day1 (i.e. 4 cycles) * Pembrolizumab 200 mg q21 up to tumor progression, intolerable toxicities or 35 cycles (approximately 2 years of therapy).

    Dietary Supplement: Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic. · Drug: Pembolizumab

Interventions

  • Dietary supplementPostbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic.

    Postbiotix-HLA™, 1 capsule (400 mg) daily PO from cycle 1 day 1 up to cycle 5 day1 (i.e. 4 cycles);

  • Dietary supplementplacebo capsule

    Agente di carica: Mannitolo; Opercolo: Idrossipropilmetilcellulosa, Carbonato di calcio, Carragenina; Agente di carica: Cellulosa microcristallina; Agenti antiagglomeranti: Sali di magnesio di acidi grassi, Biossido di silicio.

  • DrugPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab 200 mg q21 up to tumor progression, intolerable toxicities or 35 cycles (approximately 2 years of therapy).

06

What researchers measure

Primary outcomes

  1. Changes in oral and fecal microbiota composition

    Comparison of changes in the composition and diversity of microbiota in oral and fecal samples between treatment groups (pembrolizumab + Postbiotix-HLA™ vs pembrolizumab + placebo). Samples will be collected at baseline and Week 13. Microbiota composition will be analyzed using shotgun sequencing.

    Time frame: 2 years

Secondary outcomes

  1. Change in HLA Class I-expressing circulating MDSCs

    Comparison of the proportion of HLA Class I - expressing circulating MDSCs from baseline to week 13 of therapy with pembrolizumab + Postbiotix-HLA™ vs pembrolizumab + placebo, measured by flow cytometry on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood samples

    Time frame: 2 years

  2. Change in circulating regulatory T cells (Tregs)

    Comparison of the proportion of circulating Tregs from baseline to week 13 of therapy with pembrolizumab + Postbiotix-HLA™ vs pembrolizumab + placebo measured by flow cytometry on peripheral blood mononuclear cells (PBMCs) isolated from peripheral blood samples.

    Time frame: 2 years

  3. Change in tumor NLRC5 expression

    Change in tumor expression level of NLRC5 from baseline to week 13 of therapy with Postbiotix-HLA™ + pembrolizumab vs pembrolizumab + placebo assessed on tumor tissue samples

    Time frame: 2 years

  4. Incidence and severity of treatment-related immune-related adverse events (irAEs)

    Comparison of treatment-related irAEs between treatment groups (pembrolizumab + Postbiotix-HLA™ vs pembrolizumab + placebo), assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 2 years

  5. Patient-reported treatment-related symptoms using NCI-PRO-CTCAE

    Comparison of patient-reported treatment-related symptoms between treatment groups (pembrolizumab + Postbiotix-HLA™ vs pembrolizumab + placebo), assessed using the NCI PRO-CTCAE Items (Italian; Item Library Version 1.0). Patients will self-report symptom frequency, severity, and interference at each study visit using standardized questionnaires.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2030, 59 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 59 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Mar 20, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2032
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07485296
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Jan 27, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Mar 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion